Orphan Drug Pricing Heading To Negotiating Table in US?
Executive Summary
The Institute for Clinical and Economic Review is launching an initiative to adapt its value assessment approach to orphan and ultra-orphan drugs, including a possible consideration of what should be a fair return on investment for manufacturers.
You may also be interested in...
Orphan Drug Policy Changes To Be Considered Under US FDA's FY 2019 Budget Proposal
Proposed $20m funding boost for rare disease development includes review of orphan incentives, including how to potentially stimulate development in ultra-orphan diseases.
US FDA Doesn't Support Creating Ultra-Orphan Designation
Agency is already approving drugs for diseases with much smaller patient populations than the traditional rare disease, officials note.
Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'
Is the lower sale price making the opportunity for a priority review voucher less an incentive for orphan development?